Galicaftor (ABBV-2222)

Catalog No.C13476 Batch:C1347603

Product Datasheet

Technical Data

Formula	$C_{28}H_{21}F_4NO_7$					
Molecular Weight	559.46	**CAS No.**	1918143-53-9			
Solubility (25°C)*	In vitro	DMSO	100 mg/mL (178.74 mM)			
		Ethanol	100 mg/mL (178.74 mM)			
		Water	Insoluble			
	In vivo (Add solvents to the product individually and in order)	Oral Administration	Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
				5%DMSO [1]→ 40%PEG300 [2]→ 5%Tween80 [3]→ 50%ddH2O Validated by Capsid Bio labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (8.94mM)	
		Injection		5% DMSO [1]→ 95% Corn oil Validated by Capsid Bio labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.500mg/ml (4.47mM)	

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Capsid Bio tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped at 2-8°C for storage purposes.)

Preparing Stock Solutions

Biological Activity

Description	Galicaftor (ABBV-2222, GLPG2222) is a potent corrector of **CFTR** for the treatment of Cystic Fibrosis (CF).
Targets	CFTR [1]
In vitro	Galicaftor (ABBV-2222) exhibits potent in vitro functional activity in primary patient cells harboring F508del/F508del CFTR with an EC50 <10 nM. It promotes maturation of F508delCFTR, stabilizes nucleotide binding domain 1 - membrane spanning domain interface, and corrects F508delCFTR through action on membrane spanning domain 1.[2]
In vivo	Pharmacokinetic tests performed in rats on Galicaftor (ABBV-2222; GLPG-2222; 1 mg/kg, i.v.; 1 mg/kg, p.o.) showed that for this compound, T1/2 is 2.7 hours (i.v.) and for intragastric administration, the bioavailability (%F) is 74%.

Protocol (from reference)

Cell Assay:[2]

- **Cell lines**
  CFBE41o-F508del CFTR-HRP cells
- **Concentrations**
  0 - 20 μM
- **Incubation Time**
  18-24 h
- **Method**
  Galicaftor (ABBV-2222) is then added at the required concentrations and further incubated for 18-24 hours at 33 °C. The highest concentration tested is 20 μM with an 8-12 point concentration response curve using a 3-fold dilution.

References

https://pubmed.ncbi.nlm.nih.gov/31259557/ https://pubmed.ncbi.nlm.nih.gov/31732698/ https://pubmed.ncbi.nlm.nih.gov/29251932/

RETURN POLICY

Capsid Bio's Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING & STORAGE

Capsid Bio products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Capsid Bio Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Capsid Bio products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

EU Headquarters
Gajeva ulica 28, HR-10000 Zagreb, Croatia

US Headquarters
12222 Merit Dr STE 130 Dallas, Texas, 75251

UK Headquarters
121 ABILITY HOUSE, BROOKER ROAD, EN9 1JH, ESSEX

Orders: Sales@capsidbio.com
Enquiries: info@capsidbio.com
www.capsidbio.com